These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10879390)

  • 21. Managing atrial tachyarrhythmias in patients with implantable cardioverter defibrillators.
    Schaumann A
    Am J Cardiol; 1999 Mar; 83(5B):214D-217D. PubMed ID: 10089868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A guide to the design and analysis of small clinical studies.
    Kianifard F; Islam MZ
    Pharm Stat; 2011; 10(4):363-8. PubMed ID: 21140524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial.
    Exner DV; Sheldon RS; Pinski SL; Kron J; Hallstrom A
    Am Heart J; 2001 Jan; 141(1):99-104. PubMed ID: 11136493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of patient characteristics in the selection of patients for defibrillator implantation (the AVID Registry). Antiarrhythmics Versus Implantable Defibrillators.
    Curtis AB; Hallstrom AP; Klein RC; Nath S; Pinski SL; Epstein AE; Wyse G; Cannom DS; Renfroe E
    Am J Cardiol; 1997 May; 79(9):1185-9. PubMed ID: 9164882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized and nonrandomized studies: complementary or competing?
    Pandis N; Tu YK; Fleming PS; Polychronopoulou A
    Am J Orthod Dentofacial Orthop; 2014 Nov; 146(5):633-40. PubMed ID: 25439214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT.
    Gold MR; Nisam S;
    Pacing Clin Electrophysiol; 2000 Nov; 23(11 Pt 2):1981-5. PubMed ID: 11139972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An AVID dissent.
    Fogoros RN
    Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 1):1707-11. PubMed ID: 7838777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal disease and cardiac mortality in survivors of sudden cardiac death.
    Rathod A; Badheka A; Kizilbash M; Manickam P; Mohamad T; Bhat S; Afonso L; Jacob S
    Acta Cardiol; 2010 Jun; 65(3):323-8. PubMed ID: 20666271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of implantable cardioverter defibrillators in the secondary prevention of malignant ventricular arrhythmias: lessons from large studies].
    Anadolu Kardiyol Derg; 2001 Mar; 1(1):43-7, AXIV. PubMed ID: 12132492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government.
    Anderson KP
    J Interv Card Electrophysiol; 2005 Nov; 14(2):71-8. PubMed ID: 16374553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implantable cardioverter-defibrillators: expanding indications and technologies.
    Goldberger Z; Lampert R
    JAMA; 2006 Feb; 295(7):809-18. PubMed ID: 16478904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving sudden cardiac death risk stratification by evaluating electrocardiographic measures of global electrical heterogeneity and clinical outcomes among patients with implantable cardioverter-defibrillators: rationale and design for a retrospective, multicenter, cohort study.
    Waks JW; Hamilton C; Das S; Ehdaie A; Minnier J; Narayan S; Niebauer M; Raitt M; Tompkins C; Varma N; Chugh S; Tereshchenko LG
    J Interv Card Electrophysiol; 2018 Jun; 52(1):77-89. PubMed ID: 29541969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design using historical controls.
    Yen A; Simpson E; Haverkamp L; Appel S
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():61-3. PubMed ID: 15512876
    [No Abstract]   [Full Text] [Related]  

  • 37. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.
    Domanski MJ; Sakseena S; Epstein AE; Hallstrom AP; Brodsky MA; Kim S; Lancaster S; Schron E
    J Am Coll Cardiol; 1999 Oct; 34(4):1090-5. PubMed ID: 10520795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios.
    Koller MT; Stijnen T; Steyerberg EW; Lubsen J
    J Clin Epidemiol; 2008 Apr; 61(4):365-72. PubMed ID: 18313561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
    Coats AJ
    Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death.
    Spath MA; O'Brien BJ
    Pharmacoeconomics; 2002; 20(11):727-38. PubMed ID: 12201792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.